Section Navigation
Section Navigation
- Module 5 Overview
Prevention of HIV - 0%Lesson 1
Preventing Perinatal HIV TransmissionActivities- 0%Lesson 2
Preventing HIV Transmission in Persons with HIVActivities- 0%Lesson 3
Occupational Postexposure ProphylaxisLesson 1. Preventing Perinatal HIV Transmission
Learning Objective Performance Indicators
- Explain the mechanisms of perinatal HIV transmission and interventions to reduce the risks of perinatal HIV transmission
- List preferred initial antiretroviral regimens for pregnant women with HIV
- Discuss indications for use of intravenous zidovudine and cesarean section for pregnant women with HIV
- Describe recommended antiretroviral prophylaxis for infants born to pregnant women with HIV
- Summarize recommendations for initial management of infants exposed to HIV, including HIV diagnostic testing and monitoring
About this Lesson
Learning Objective Performance Indicators
- Explain the mechanisms of perinatal HIV transmission and interventions to reduce the risks of perinatal HIV transmission
- List preferred initial antiretroviral regimens for pregnant women with HIV
- Discuss indications for use of intravenous zidovudine and cesarean section for pregnant women with HIV
- Describe recommended antiretroviral prophylaxis for infants born to pregnant women with HIV
- Summarize recommendations for initial management of infants exposed to HIV, including HIV diagnostic testing and monitoring
Activities in this Lesson
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Lesson 2
Funded by
Health Resources and Services Administration (HRSA)
Created at
University of Washington
An AETC Program
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE approved byOregon Nurses Association
Copyright © 2025 National HIV Curriculum
The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant